Product Description
AstraZeneca is developing AZD-3427 as a treatment for heart failure. (Sourced from: https://www.astrazeneca.com/our-therapy-areas/pipeline.html)
Mechanisms of Action: Relaxin Mimetic
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Canada, China, Czech Republic, Denmark, Germany, Italy, Japan, Netherlands, Poland, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Heart Failure|Hypertension, Pulmonary|Pulmonary Heart Disease
Phase 1: Heart Failure, Chronic|Heart Failure, Systolic|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-513143-82-00 |
D8330C00004 | P1 |
Recruiting |
Kidney Diseases|Heart Failure, Chronic|Heart Failure, Systolic |
2025-09-30 |
2025-05-02 |
Treatments |
|
NCT05737940 |
Re-PHIRE | P2 |
Completed |
Heart Failure|Hypertension, Pulmonary |
2025-07-15 |
12% |
2025-09-25 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
jRCT2041230006 |
jRCT2041230006 | P2 |
Recruiting |
Hypertension, Pulmonary|Pulmonary Heart Disease|Heart Failure |
2025-06-17 |
|||
2022-502382-25-00 |
D8330C00003 | P2 |
Active, not recruiting |
Pulmonary Heart Disease|Heart Failure|Hypertension, Pulmonary |
2025-06-02 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|